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Commentary: an imperfect compromise
Martin Dennis
Boter and colleagues have proposed a compromise to
obtaining fully informed consent before enrolment
for randomised trials that have primary outcomes
based on a subjective measure, which makes blinding
impossible and bias likely. This compromise aims to
involve the patient and show them as much respect as
possible. As with all compromises it is imperfect.
From the trialists’ point of view it still has several
drawbacks compared with obtaining consent only for
follow up.
Telling patients that there is a secret additional
research question is likely to reduce the proportion of
patients who agree to participate and thus the general-
isability of the trial’s results. The number of patients
who refused to participate in the study, and their char-
acteristics compared with participants, would indicate
the size of this problem.
The wording of the patient information is bound to
raise curiosity about the nature of the additional ques-
tions. Some participants may make the link between
the intervention they receive and the questions asked
at follow up. This would introduce an unknown
amount of bias, although it is likely to be small.
The reassurance given to patients that the
“additional question entails no risk” is potentially mis-
leading. Firstly, if the intervention improves outcome
then those in the control group will have a risk of a
worse outcome. This statement could therefore be
used only when the patient would have access to the
intervention only within the trial and where the control
arm would receive normal care. Also, in our trial, those
allocated a stroke family care worker judged them-
selves more helpless than controls at follow up. We
have subsequently shown that helplessness in these
stroke patients was associated with poorer long term
survival, even after we adjusted for important prognos-
tic factors.1 No treatment should be assumed to be free
of adverse effects. Perhaps the reassurance should read
that there are no likely adverse effects.
No doubt the ethicists, who focus mainly on the
rights of the individual, will see this compromise as
unacceptable. They do not have to struggle with the
everyday double standards applied to consent proce-
dures in research compared with those in routine care
and audit. We have no universally accepted solution to
the clinical trialists’ dilemma that to provide treatments
of proved benefit to many future patients (and to avoid
putting them at risk) we may sometimes have to com-
promise the rights of current patients to be fully
informed in advance about treatment options and
research methods.
Of course, we shouldn’t have to rely on what the
ethicists or the trialists think. Surely, we should involve
potential participants in the design of the consent pro-
cedure. We should ask the patients who were enrolled
in this study for their views. Did they feel, once they had
been informed, that they had been treated with
respect? Was the approach taken in this case
acceptable to them?
Competing interests: None declared.
1 Lewis SC, Dennis MS, O’Rourke SJ, Sharpe M. Negative attitudes among
short-term stroke survivors predict worse long-term survival. Stroke
2001;32:1640-5.
A memorable patient
Compartment syndrome
The 6 year old boy arrived in the night with a painful and swollen
elbow after a fall. His supracondylar fracture was manipulated, the
subsequent x ray films looked excellent, and he was discharged.
He returned two days later with severe pain and a blistered,
swollen forearm. The diagnosis of compartment syndrome
crossed my mind, but my registrar soon ruled it out. He said,
“Swelling is quite common in this fracture. The child’s pulses are
palpable, and sensations are fine. Send him home.” Being a
beginner, I did not have enough clinical knowledge and
experience to challenge the decision. Who would challenge his
senior, anyway? Hence the child was discharged the second time
with a follow up appointment in the clinic after two days.
This patient’s subsequent visit was the most devastating
experience of my professional life. He was reviewed in the clinic
by my professor (who eventually turned out to be the architect of
my future orthopaedic career). As luck would have it, the senior
registrar was on annual leave that day—good for him, bad for me.
The puffy forearm had all the signs of a well established
compartment syndrome (and a “neglected” one), with no
movement, pulses, or sensations. My professor was furious. His
words burnt my ears like molten lead. I stood before him like a
culprit in a witness box with my hands tied behind my back.
There were no pauses and no opportunities for explanations. In
those few minutes of constant fire, I saw my clinical career
collapsing like a house made of playing cards. I was almost in
tears, and I felt guilty, worthless, and incompetent.
The subsequent decompression was obviously unsuccessful,
and the child developed Volkmann’s ischaemic contracture.
I knew this stigma would remain with me forever. And so it did.
The story was told over and over again to each new group of
undergraduate and postgraduate students. It was referred to as
“Dr Anwar’s case.” My boss always emphasised the importance of
early identification of this condition. Interestingly, my registrar
would always nod his head in agreement like a true disciple
without sensing the red hot rage in my chest.
Ten years later, when I visited my professor in India, I tried to
clear my name by explaining things to him again. He replied: “My
boy, what happens when you see a child with a supracondylar
fracture of the humerus now? You remember me, you remember
that child, and you remember compartment syndrome. That is
what it was all about.” I will never forget those golden words that
were so true and meaningful.
Rahij Anwar clinical fellow in trauma and orthopaedics,Maidstone
Hospital, Kent
rahijanwar@hotmail.com
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